Skip to main content

Table 4 Clinical characteristics, hormonal levels, metabolic profile and PAF-AH activity of the apoC1 rs4420638 genotypes in PCOS patients and controls

From: Effects of apoC1 genotypes on the hormonal levels, metabolic profile and PAF-AH activity in Chinese women with polycystic ovary syndrome

 

Controls

PCOS

AA (n = 379)

AG + GG (n = 121 + 6)

AA (n = 435)

AG + GG (n = 134 + 6)

Age (yr)

28.18 ± 4.10

27.28 ± 4.41a

24.68 ± 4.01a, b

24.60 ± 3.81a, b

BMI (kg/m2)

21.17 ± 2.96

20.88 ± 2.74

23.24 ± 4.32a, b

22.68 ± 4.03a, b

Waist circumference (cm)

73.41 ± 8.21

73.36 ± 8.36

80.13 ± 11.67a, b

77.96 ± 11.22a, b

Waist-to-hip ratio

0.81 ± 0.06

0.82 ± 0.06

0.86 ± 0.07a, b

0.84 ± 0.07a, b

F-G score

0.22 ± 0.69

0.26 ± 0.82

1.73 ± 2.07a, b

1.71 ± 2.08a, b

Acne grade score

0.10 ± 0.30

0.08 ± 0.27

0.66 ± 0.94a, b

0.53 ± 0.86a, b

SBP (mmHg)

113.42 ± 11.55

112.98 ± 11.84

114.89 ± 10.42a

113.78 ± 11.65

DBP (mmHg)

73.97 ± 8.88

73.40 ± 8.75

76.35 ± 9.08a, b

74.70 ± 8.99

Ovarian volume (ml)

7.88 ± 2.76

7.47 ± 3.24

10.22 ± 3.92a, b

9.95 ± 4.63a, b

Hormonal levels

E2 (pmol/L)

322.08 ± 341.61

367.37 ± 376.94

281.07 ± 279.42b

293.07 ± 245.85

TT (nmol/L)

1.54 ± 0.54

1.53 ± 0.56

2.41 ± 0.77a, b

2.45 ± 0.77a, b

LH (IU/L)

8.53 ± 10.38

9.28 ± 13.76

13.24 ± 8.57a, b

15.85 ± 15.91a, b, c

FSH (IU/L)

6.59 ± 2.84

6.89 ± 3.34

5.95 ± 2.27a, b

6.12 ± 2.11b

LH/FSH

1.31 ± 1.24

1.29 ± 1.54

2.28 ± 1.18a, b

2.58 ± 1.45a, b

Metabolic profile

Fasting Ins (pmol/L)

64.87 ± 32.78

73.28 ± 46.17a

109.10 ± 77.82a, b

96.60 ± 60.98a, b

Fasting Glu (mmol/L)

5.26 ± 0.46

5.42 ± 1.22a

5.38 ± 0.71a

5.36 ± 0.93a

HOMA-IR

2.22 ± 1.22

2.73 ± 3.13a

3.89 ± 3.31a, b

3.46 ± 2.80a, b

TG (mmol/L)

1.02 ± 0.93

1.08 ± 0.76

1.46 ± 1.50a, b

1.29 ± 0.73a

TC (mmol/L)

4.22 ± 0.71

4.31 ± 0.66

4.35 ± 0.80a

4.57 ± 0.82a, b, c

HDL-C (mmol/L)

1.52 ± 0.32

1.48 ± 0.29

1.37 ± 0.34a, b

1.42 ± 0.36a, b

LDL-C (mmol/L)

2.32 ± 0.61

2.44 ± 0.60

2.51 ± 0.75a

2.66 ± 0.77a, b, c

non-HDL-C (mmol/L)

2.70 ± 0.63

2.83 ± 0.65

2.98 ± 0.81a, b

3.14 ± 0.78a, b, c

AI

1.87 ± 0.65

2.02 ± 0.74a

2.37 ± 1.05a, b

2.37 ± 0.91a, b

ApoA1 (g/L)

1.46 ± 0.22

1.44 ± 0.18

1.41 ± 0.21a

1.43 ± 0.22a

ApoB (g/L)

0.74 ± 0.17

0.78 ± 0.17a

0.81 ± 0.20a, b

0.85 ± 0.20a, b, c

ApoB/apoA1

0.52 ± 0.14

0.55 ± 0.16a

0.59 ± 0.18a, b

0.61 ± 0.19a, b, c

PAF-AH activityd

Plasma PAF-AH (nmol/min/ml)

47.80 ± 10.91

50.08 ± 10.39a

47.54 ± 12.27b

47.05 ± 15.17

H-PAF-AH (nmol/min/ml)

5.09 ± 1.51

5.30 ± 1.52

4.64 ± 1.89a, b

4.77 ± 2.01

ApoB-PAF-AH (nmol/min/ml)

42.74 ± 10.09

44.78 ± 9.50a

42.91 ± 11.34

42.28 ± 13.74

ApoB-PAF-AH/H-PAF-AH

8.85 ± 2.61

8.88 ± 2.09

10.91 ± 4.17a, b

9.48 ± 2.60

  1. Values are presented as the mean ± SD
  2. Comparisons of all parameters were corrected for differences in age and BMI between the two subgroups except the parameters of age and BMI
  3. a P < 0.05, compared with AA genotype subgroup in controls
  4. bP < 0.05, compared with AG + GG genotype subgroup in controls
  5. cP < 0.05, compared with AA genotype subgroup in PCOS patients
  6. d Controls: AA (n = 207), AG + GG (n = 67 + 3); PCOS: AA (n = 219), AA + AG (n = 60 + 2)